The Cognition Group (TCG) has updated its hardware for the Signal Enhancement System (SES). This technological enhancement will allow patient interviews to be recorded and viewed in a more precise, higher quality format and will further improve international clinical trials.
Clinical trials in the Central Nervous System (CNS) have been riddled with human error as long as they have existed. Problems include inconsistent or biased ratings, patients with incorrect diagnoses participating in the study, or even rating of the wrong interview. All of these issues have decreased the signal in CNS clinical trials.
SES is a system that resolves these issues through interview quality control, study assessment standardization, and scale rating integrity at the investigating sites. The system, which has been used in CNS clinical trials for the last three years, not only ensures that interviews are conducted according to protocol, but also facilitates expert and consensus ratings.
Data presented at recent conferences show that the SES controls for raters' enrollment bias and expectancy bias while ensuring that patients with the correct diagnosis are entered into the study. It addresses in-study rater variance by identifying raters’ nonconformity to pre-set rating standards, consequently enhancing data quality. The technology's strength is based on more focused patient evaluation and controlled impact of inconsistent rater performance on trial outcomes.
Recently, TCG has updated all of its hardware that it distributes to sites by replacing all of its laptops with a newer model; adding a 180 degree, higher pixel motion-detecting camera; and including a USB microphone that can record conversation up to 50 feet away. “We are very excited about this update,” said Subhash Goswami, Chief Operating Officer of TCG. “SES has revolutionized the way in which CNS clinical trials are conducted. Updating the hardware allows us to further improve the industry standards and greatly reduce errors in clinical trials.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.